These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 33078436

  • 1. Clinical trial risk in leukemia: Biomarkers and trial design.
    Li AJ, Dhanraj JP, Lopes G, Parker JL.
    Hematol Oncol; 2021 Feb; 39(1):105-113. PubMed ID: 33078436
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Three hematologic malignancies in the same patient: chronic lymphocytic leukemia, followed by chronic myeloid leukemia and acute myeloid leukemia.
    Fattizzo B, Radice T, Cattaneo D, Pomati M, Barcellini W, Iurlo A.
    Clin Lab; 2014 Feb; 60(11):1929-32. PubMed ID: 25648037
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clofarabine.
    Drugs R D; 2004 Feb; 5(4):213-7. PubMed ID: 15230627
    [Abstract] [Full Text] [Related]

  • 6. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
    Reyes C, Engel-Nitz NM, DaCosta Byfield S, Ravelo A, Ogale S, Bancroft T, Anderson A, Chen M, Matasar M.
    Oncologist; 2019 Sep; 24(9):1219-1228. PubMed ID: 30808814
    [Abstract] [Full Text] [Related]

  • 7. Impact of biomarkers on clinical trial risk in breast cancer.
    Parker JL, Lushina N, Bal PS, Petrella T, Dent R, Lopes G.
    Breast Cancer Res Treat; 2012 Nov; 136(1):179-85. PubMed ID: 23007573
    [Abstract] [Full Text] [Related]

  • 8. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
    Bewersdorf JP, Stahl M, Zeidan AM.
    Leuk Lymphoma; 2019 Jun; 60(6):1354-1369. PubMed ID: 30652518
    [Abstract] [Full Text] [Related]

  • 9. Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action.
    Tillie NA, Parker JL, Feld JJ.
    Can J Gastroenterol Hepatol; 2016 Jun; 2016():6260271. PubMed ID: 27446855
    [Abstract] [Full Text] [Related]

  • 10. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R.
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [Abstract] [Full Text] [Related]

  • 11. The Anti-Leukemic Activity of Natural Compounds.
    Cotoraci C, Ciceu A, Sasu A, Miutescu E, Hermenean A.
    Molecules; 2021 May 05; 26(9):. PubMed ID: 34063044
    [Abstract] [Full Text] [Related]

  • 12. New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia.
    Click ZR, Seddon AN, Bae YR, Fisher JD, Ogunniyi A.
    Pharmacotherapy; 2018 Nov 05; 38(11):1143-1154. PubMed ID: 30220082
    [Abstract] [Full Text] [Related]

  • 13. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH, Johnson JR, Pazdur R.
    Clin Cancer Res; 2005 Jan 01; 11(1):12-9. PubMed ID: 15671523
    [Abstract] [Full Text] [Related]

  • 14. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
    Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, McDougal A, Pilaro A, Chiang R, Gootenberg JE, Keegan P, Pazdur R.
    Clin Cancer Res; 2010 Sep 01; 16(17):4331-8. PubMed ID: 20601446
    [Abstract] [Full Text] [Related]

  • 15. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A, Schmitt AM, Speich B, Naudet F, Agarwal A, Pereira TV, Sclafani F, Herbrand AK, Briel M, Martin-Liberal J, Schmid T, Ewald H, Ioannidis JPA, Bucher HC, Kasenda B, Hemkens LG.
    JAMA Netw Open; 2020 Nov 02; 3(11):e2024406. PubMed ID: 33170262
    [Abstract] [Full Text] [Related]

  • 16. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.
    Gormley NJ, Turley DM, Dickey JS, Farrell AT, Reaman GH, Stafford E, Carrington L, Marti GE.
    Cytometry B Clin Cytom; 2016 Jan 02; 90(1):73-80. PubMed ID: 26108351
    [Abstract] [Full Text] [Related]

  • 17. Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis.
    Parker JL, Kuzulugil SS, Pereverzev K, Mac S, Lopes G, Shah Z, Weerasinghe A, Rubinger D, Falconi A, Bener A, Caglayan B, Tangri R, Mitsakakis N.
    Cancer Med; 2021 Mar 02; 10(6):1955-1963. PubMed ID: 33620160
    [Abstract] [Full Text] [Related]

  • 18. Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases.
    Nagai S, Ozawa K.
    Invest New Drugs; 2018 Jun 02; 36(3):487-495. PubMed ID: 29453626
    [Abstract] [Full Text] [Related]

  • 19. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL, Comeau JM.
    Ann Pharmacother; 2013 Nov 02; 47(11):1540-6. PubMed ID: 24265264
    [Abstract] [Full Text] [Related]

  • 20. In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia.
    Aleskog A, Larsson R, Höglund M, Kristensen J, Nygren P, Lindhagen E.
    Anticancer Drugs; 2005 Mar 02; 16(3):277-83. PubMed ID: 15711179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.